These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
596 related articles for article (PubMed ID: 36341760)
1. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. Zou Y; Xie J; Zheng S; Liu W; Tang Y; Tian W; Deng X; Wu L; Zhang Y; Wong CW; Tan D; Liu Q; Xie X Int J Surg; 2022 Nov; 107():106936. PubMed ID: 36341760 [TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns. Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675 [TBL] [Abstract][Full Text] [Related]
3. Association Between Diverse Cell Death Patterns Related Gene Signature and Prognosis, Drug Sensitivity, and Immune Microenvironment in Glioblastoma. Li J; Song Z; Chen Z; Gu J; Cai Y; Zhang L; Wang Z J Mol Neurosci; 2024 Jan; 74(1):10. PubMed ID: 38214842 [TBL] [Abstract][Full Text] [Related]
4. Prediction of clinical prognosis and drug sensitivity in hepatocellular carcinoma through the combination of multiple cell death pathways. Chen Q; Zhang C; Meng T; Yang K; Hu Q; Tong Z; Wang X Cell Biol Int; 2024 Dec; 48(12):1816-1835. PubMed ID: 39192561 [TBL] [Abstract][Full Text] [Related]
5. Machine learning-based biomarker screening for acute myeloid leukemia prognosis and therapy from diverse cell-death patterns. Qin Y; Pu X; Hu D; Yang M Sci Rep; 2024 Aug; 14(1):17874. PubMed ID: 39090256 [TBL] [Abstract][Full Text] [Related]
6. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype. Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W Front Immunol; 2021; 12():749459. PubMed ID: 34603338 [TBL] [Abstract][Full Text] [Related]
7. Integrative analysis of multiple cell death model for precise prognosis and drug response prediction in gastric cancer. Su W; Shi X; Wen X; Li X; Zhou J; Zhou Y; Ren F; Kang K Discov Oncol; 2024 Oct; 15(1):532. PubMed ID: 39377861 [TBL] [Abstract][Full Text] [Related]
8. Constructing a Prognostic Model of Uterine Corpus Endometrial Carcinoma and Predicting Drug-Sensitivity Responses Using Programmed Cell Death-Related Pathways. Meng J; Zong C; Wang M; Chen Y; Zhao S J Cancer; 2024; 15(10):2948-2959. PubMed ID: 38706893 [No Abstract] [Full Text] [Related]
9. Characterization of prognostic signature related with twelve types of programmed cell death in lung squamous cell carcinoma. Li S; Ding B; Weng D J Cardiothorac Surg; 2024 Oct; 19(1):569. PubMed ID: 39354528 [TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer. Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558 [TBL] [Abstract][Full Text] [Related]
11. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer. Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184 [TBL] [Abstract][Full Text] [Related]
12. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer. Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer. Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333 [TBL] [Abstract][Full Text] [Related]
14. Identification and analysis of diverse cell death patterns in diabetic kidney disease using microarray-based transcriptome profiling and single-nucleus RNA sequencing. Luo Y; Liu L; Zhang C Comput Biol Med; 2024 Feb; 169():107780. PubMed ID: 38104515 [TBL] [Abstract][Full Text] [Related]
15. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs. Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K Front Immunol; 2022; 13():982486. PubMed ID: 36119101 [TBL] [Abstract][Full Text] [Related]
16. Integrated multi-cohorts for characterizing the immunogenomic landscape and predicting drug response in triple-negative breast cancer. Su D; Chi M; Wang S; Di S; Zhang H; Lu Q; Yu Y; Xiong Y; Wei H; Lv Y; Zuo Y; Yang L Brief Funct Genomics; 2022 May; 21(3):188-201. PubMed ID: 35348574 [TBL] [Abstract][Full Text] [Related]
17. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer. Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S Front Immunol; 2023; 14():1263537. PubMed ID: 37767092 [TBL] [Abstract][Full Text] [Related]
18. Identification an innovative classification and nomogram for predicting the prognosis of thyroid carcinoma patients and providing therapeutic schedules. Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J J Cancer Res Clin Oncol; 2023 Nov; 149(16):14817-14831. PubMed ID: 37596371 [TBL] [Abstract][Full Text] [Related]
19. Turning up a new pattern: Identification of cancer-associated fibroblast-related clusters in TNBC. Xie J; Zheng S; Zou Y; Tang Y; Tian W; Wong CW; Wu S; Ou X; Zhao W; Cai M; Xie X Front Immunol; 2022; 13():1022147. PubMed ID: 36275659 [TBL] [Abstract][Full Text] [Related]
20. CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer. Cheng T; Wu Y; Liu Z; Yu Y; Sun S; Guo M; Sun B; Huang C Front Immunol; 2022; 13():970950. PubMed ID: 36052076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]